CCO Treatment Updates
Clinical Issues and Future Directions in Hematologic Malignancies
Virtual Presentations
Multiple Myeloma
|
|
|
 Amitabha Mazumder, MD, discusses new data in multiple myeloma presented at the 2007 hematology meeting. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss frontline induction therapy strategies for patients with newly diagnosed multiple myeloma
- Cite cytogenetic and hematologic factors prognostic for outcomes in the treatment of patients with multiple myeloma
- Describe recent clinical trial results regarding frontline therapy for elderly myeloma patients and others who are not candidates for autologous stem cell transplantation
- List novel agents emerging in the setting of multiple myeloma
|
Clinical Issues and Future Directions in Hematologic Malignancies: Multiple Myeloma
 |
|
Amitabha Mazumder, MD, discusses results presented at the 2007 hematology meeting regarding chronic lymphocytic leukemia.
Format: Microsoft PowerPoint (.ppt) | File size: 1,151 KB
|
Non-Hodgkin’s Lymphoma
|
|
|
Sandra J. Horning, MD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with non-Hodgkin’s lymphoma. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the results of recent studies regarding the use of FDA-approved and investigational agents for the treatment of non-Hodgkin’s lymphoma (NHL)
- Discuss new insights into the etiology and prognostic indicators of NHL
- Summarize new developments in the management of adverse events related to the treatment of NHL
|
Non-Hodgkin’s Lymphoma
 |
|
Sandra J. Horning, MD, discusses recent data on current and novel therapeutic approaches for treating patients with non-Hodgkin’s lymphoma.
Format: Microsoft PowerPoint (.ppt) | File size: 2,747 KB
|
Acute Leukemias
|
|
|
Farhad Ravandi, MD, discusses results presented at the 2007 hematology meeting regarding acute leukemias. Learning Objectives
Upon completion of this activity, participants should be able to:
- Cite cytogenetic abnormalities associated with poor outcomes in acute myeloid leukemia and acute lymphocytic leukemia
- Discuss the use of alternatives to chemotherapy for the treatment of acute promyelocytic leukemia
- Explain the use of pediatric regimens for the treatment of acute lymphocytic leukemia in adult patients
- Compare outcomes with tyrosine kinase inhibitors used in the treatment of acute leukemias
- Discuss the use of hyper-CVAD in the treatment of acute leukemias
|
Clinical Issues and Future Directions in Hematologic Malignancies: Acute Leukemias
 |
|
Farhad Ravandi, MD, discusses results presented at the 2007 hematology meeting regarding ALL, AML, and APL.
Format: Microsoft PowerPoint (.ppt) | File size: 2,351 KB
|
Myelodysplastic Syndromes
|
|
|
Allen S. Yang, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with myelodysplastic syndromes. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the results of recent studies regarding the use of FDA-approved and investigational agents for the treatment of myelodysplastic syndrome (MDS)
- Discuss new insights into the etiology and prognostic indicators of MDS
- Summarize new developments in the management of adverse events related to the treatment of MDS
|
Myelodysplastic Syndromes
 |
|
Allen S. Yang, MD, PhD, discusses recent data on current and novel therapeutic approaches for treating patients with myelodysplastic syndromes.
Format: Microsoft PowerPoint (.ppt) | File size: 801 KB
|
Chronic Myeloid Leukemia
|
|
|
Neil Shah, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with chronic myeloid leukemia. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the results of recent studies regarding the use of FDA-approved and investigational agents for the treatment of chronic myeloid leukemia (CML)
- Discuss new insights into the etiology and prognostic indicators of CML
- Summarize new developments in the management of adverse events related to the treatment of CML
|
Chronic Myeloid Leukemia
 |
|
Neil Shah, MD, PhD, discusses recent data on current and novel therapeutic approaches for treating patients with chronic myeloid leukemia.
Format: Microsoft PowerPoint (.ppt) | File size: 1,210 KB
|
Chronic Lymphocytic Leukemia
- Michael J. Keating, MB BS
|
|
|
Michael J. Keating, MB BS, discusses results presented at the 2007 hematology meeting regarding chronic lymphocytic leukemia. Learning Objectives
Upon completion of this activity, participants should be able to:
- List factors prognostic for outcomes in the treatment of chronic lymphocytic leukemia
- Describe the use of alemtuzumab in combination chemotherapy regimens for patients with chronic lymphocytic leukemia
- Discuss recent clinical trial data regarding the treatment of elderly patients with chronic lymphocytic leukemia
- Explain clinical trial results regarding bendamustine in the clinical management of patients with chronic lymphocytic leukemia
- Define monoclonal B-cell lymphocytosis and recall its treatment
|
Clinical Issues and Future Directions in Hematologic Malignancies: Chronic Lymphocytic Leukemia
 |
|
Michael J. Keating, MD, discusses results presented at the 2007 hematology meeting regarding chronic lymphocytic leukemia.
Format: Microsoft PowerPoint (.ppt) | File size: 818 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|